MYC and glioblastoma: Cell-based assays, such as c-MYC promoter-driven reporter gene assays (e.g., luciferase assays) in relevant cancer cell lines (like glioblastoma cells known to overexpress c-MYC), would be essential to determine if EGCG treatment leads to repression of c-MYC transcription.